Puretech Health Plc · LSE:PRTC
Puretech Health — Investor Presentation (October 2026)
39 slides from Puretech Health's investor presentation, October 2026
Slide 1: PRTC Presentation October 2026
PRTC Presentation October 2026
Slide 2: Important Information
Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer session and any document or material distributed at or in co
Slide 3: PureTech Overview
PureTech Overview Deploying our differentiated hub-and-spoke model to give life to science and transform innovation into value Maximize Stakeholder Benefits Strong Fundamentals PATIENT BENEFIT & • Deliver high-impact medicines • Capital-efficient & self-funded model SHAREHOLDER for patients VALUE •
Slide 4: Our Proven and Seasoned Team
Our Proven and Seasoned Team Executive Team Robert Lyne Charles Sherwood, JD Michael Inbar, CPA, MBA Allison Mead Talbot Chief Executive Officer & Chief Operating Officer & Chief Accounting Officer Senior VP, Communications BOD Member General Counsel Former CEO at Arix Bioscience (acq. Former VP, Co
Slide 5: Our World Class Board of Directors
Our World Class Board of Directors Our board has contributed to regulatory approvals of over 15 drugs and has led multi-billion-dollar strategic transactions Sharon Barber-Lui Robert Langer, ScD John LaMattina, PhD Interim Board Chair Board Board CFO & Senior VP of Teva Pharma, Former CFO of Merck &
Slide 6: A Diversified Portfolio Well-Positioned for Significant Upside
A Diversified Portfolio Well-Positioned for Significant Upside PureTech Economics Clinical Maturity Equity1 Non-dilutive Celea Therapeutics 1-3% tiered royalties2 on Phase 3 ongoing ~$300M post-money 35.4% deupirfenidone net sales + up to $190M valuation following financing in milestones + 20% subli
Slide 7: Launching Innovation From Existing Pharmacology
aunching nnovation rom xisting pharmacology Deploying our L.I.F.E Model to systematically unlock therapeutic potential Goals • At least 3 Concept1-stage programs each year • Additional details around our progress in H1 2027 Approach Target Identify Drugs Pinpoint Design Conduct Significant With Vali
Slide 8: Case Studies of Our Model
Case Studies of Our Model Target Cause of Significant Validated Pharmacology Novel Solutions Limitations Patient Need • PureTech invented & • ~21M people worldwide patented combination of are affected1 • Xanomeline previously xanomeline with demonstrated compelling • Historical antipsychotics • Dose
Slide 9: Transforming care for people living with idiopathic pulmonary fibrosis (IPF)
Transforming care for people living with idiopathic pulmonary fibrosis (IPF) Stage of Development: Phase 3 ongoing PureTech’s Economic Interest: 35.4%1 + 1-3% tiered royalties2 on deupirfenidone annual net sales + up to $190M in milestone payments $180M financing completed on July 1, 2026 + 20% subl
Slide 10: IPF is a Progressive and Fatal Disease With Significantly Unaddressed Patient Population
Idiopathic Pulmonary Fibrosis (IPF) is a Progressive and Fatal Disease With a Significantly Unaddressed Patient Population >232,000 ~2-5 years IPF patients in the U.S. & EU51 Involves scarring of the lungs, leading Life expectancy of IPF to shortness of breath and loss of lung without treatment3 fun
Slide 11: Deupirfenidone Is a Novel Compound for the Treatment of IPF
Deupirfenidone Is a Novel Compound for the Treatment of IPF STRUCTURE OVERVIEW DEUTERIUM ▶ Leverages clinically validated pirfenidone1 SUBSTITUTION ▶ NCE/505b2 pathway Strategically placed deuterium (heavy ▶ Deupirfenidone has demonstrated ability to hydrogen) at site of enhance parent drug exposure
Slide 12: In Phase 2b Trial, Deupirfenidone 825 mg TID Stabilized Lung Function
In Phase 2b Trial, Deupirfenidone 825 mg TID Stabilized Lung Function, Achieving Rate of Decline Similar to Healthy Older Adults Change from Baseline in Forced Vital Capacity (FVC) Over 26 Weeks (mL) 0 -20 -21.5 mL -15 to -25 mL -40 -60 FVC decline for deupirfenidone 825 mg TID at 26 weeks -80 in EL
Slide 13: Initial Open Label Extension Data Demonstrated Strong and Durable Efficacy
Initial Open Label Extension Data Demonstrated Strong and Durable Efficacy with Deupirfenidone 825 mg TID over at Least 52 Weeks Change in Forced Vital Capacity (FVC) Over 52 Weeks -30 mL to -50 mL1 50 Healthy Older Adults 0 Expected natural lung function decline Change in FVC from Baseline (mL) -50
Slide 14: Deupirfenidone Has Demonstrated Potential for Best-in-class Treatment Effect
Deupirfenidone Has Demonstrated Potential for Best-in-class Treatment Effect FVC Relative Benefit Over Placebo Background Therapy Indirect comparison. Not based on head-to-head data. ELEVATE Phase 2 Deupirfenidone 825 mg (Ph 2b ELEVATE IPF 26 weeks) 81% No Background Deupirfenidone 825 mg (Ph 2b ELE
Slide 15: Phase 3 Trial is Head-to-head vs. Pirfenidone
Phase 3 Trial is Head-to-head vs. Pirfenidone Design Overview Comparator Head-to-head vs. pirfenidone; no background therapy Deupirfenidone 825 mg TID Arms Pirfenidone 801 mg TID Primary Change from baseline in absolute forced vital capacity (FVC) at 52 weeks Endpoint Based on feedback from the FDA,
Slide 16: Dedicated to transforming the treatment paradigm for hematological malignancies
Dedicated to transforming the treatment paradigm for hematological malignancies Stage of Development: Phase 2 Ready PureTech’s Economic Interest: 100%1 1 Relevant ownership interests in Gallop Oncology as of June 30, 2026. 16
Slide 17: High-Risk MDS is a Devastating Bone Marrow Cancer With Poor Survival
High-Risk Myelodysplastic Syndrome (HR-MDS) is a Devastating Bone Marrow Cancer With Poor Survival Poor Survival Outcomes1-5 Significant Unmet Need4 <2 years 1 drug class Frontline Approved for 1st line MDS Median survival following (Hypomethylating Agents or diagnosis with HR-MDS HMAs) 3-6 months 1
Slide 18: LYT-200 Targets Galectin-9, a Key Driver in Myeloid Malignancies
LYT-200 Targets Galectin-9, a Key Driver in Myeloid Malignancies Galectin-9: LYT-200: Groundbreaking Target Mutation-Agnostic, Dual MOA • Oncogenic driver and potent Gear 1 immunosuppressor Kills cancer cells • Apoptosis directly • DNA damage • Promotes multiple immunosuppressive pathways Gear 2 • B
Slide 19: Dose Response Observed in the Phase 1b Study
Dose Response Observed in the Phase 1b Study Combined MDS and AML population, efficacy evaluable (EE*) Single Agent Combination ORR 10% | SD 60% | 16 mg/kg DCR 70% RP2D cCR 32.4% | ORR 43.2% ORR 25% | SD 25% | 12 mg/kg SD 45.9% | DCR 89.1% 12 mg/kg DCR 50% cCR 20% | ORR 30% ORR 14.3% | SD 57.1% | 7.
Slide 20: Compelling Topline Data in R/R HR-MDS at 12 mg/kg Combo
Compelling Topline Data in R/R HR-MDS at 12 mg/kg Combo LYT-200 Combination in R/R HR-MDS 12 mg/kg Intent-to-Treat (ITT) Efficacy Evaluable1 Population Population (n=12) (n=11) Complete Response (CR) Rate 25% 27.3% Partial Response (PR) Rate 8.3% 9.1% Efficacy CR+PR Rate 33.3% 36.4% Marrow Complete
Slide 21: Design of Phase 2 STRIDE-MDS Study in R/R HR-MDS
Design of Phase 2 STRIDE-MDS Study in R/R HR-MDS The Study of Two Regimens Investigating Dose and Efficacy of LYT-200 in Relapsed/Refractory High-Risk MDS First Patient In Last Patient In Patient Population (N=125) LYT-200 12 mg/kg + • Post-HMA R/R MDS; high-risk by FDA HMA (N=50) accepted criteria
Slide 22: Inventing and developing new medicines for neuropsychiatric disorders
Inventing and developing new medicines for patients with depression, anxiety, and other Nasdaq: SPTX debilitating neuropsychiatric disorders PureTech’s Economic Interest: 31.2%1 + 3-5% tiered royalties on Glyph product Stage of Development: Phase 2b Ongoing net sales; Modest developmental and commer
Slide 23: Large Unmet Need for New Therapies for Depression and Anxiety
There is Large Unmet Need for New Therapies for Depression and Anxiety Depression is Disabling and Deadly ~332M ~359M ~20x people with anxiety increase in suicide risk in people with MDD disorders worldwide1 people with MDD3 worldwide1 Top 3 ~60% Suicide is a top 3 cause of of MDD patients also deat
Slide 24: Seaport is Turning the Tide on Mental Health
Seaport is Turning the Tide on Mental Health CLINICAL VALIDATION GLYPH PLATFORM PROVEN TEAM Advancing clinically validated Using Glyph to overcome Leveraging team’s expertise to mechanisms held back by issues limitations and create novel drug optimize clinical trials and drive Glyph can address cand
Slide 25: Pipeline of Novel Treatments for Neuropsychiatric Disorders
Pipeline of Novel Treatments for Neuropsychiatric Disorders ANTICIPATED SEAPORT PROGRAMS1 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES Data from Phase 2b GlyphAllo (SPT-300) Major depressive disorder (MDD) BUOY-1 trial expected Glyph Allopregnanolone H1 2027 Designed to overcome oral bioavailabili
Slide 26: First new mechanism to treat schizophrenia in over 50 years
First new mechanism to treat schizophrenia in over 50 years Stage of Development: Commercial PureTech’s Economic Interest: 2% royalty on annual Cobenfy sales above $2B + regulatory & commercial milestones 26
Slide 27: Case Study of Clinical & Financial Success: Karuna Therapeutics
Case Study of Clinical & Financial Success: Karuna Therapeutics Acquired by Bristol Myers Squibb for $14 billion on March 18, 2024 CLINICAL SUCCESS FINANCIAL SUCCESS ▶ (formerly Karuna’s KarXT) now FDA approved for the treatment of schizophrenia in adults ▶ 1st new mechanism for treating schizophren
Slide 28: Cobenfy Economics to PureTech Based on Analyst Forecasts
Cobenfy Economics to PureTech Based on Analyst Forecasts as of August 11, 2026 Potential ~$50 million in future economic value to PureTech between 2026-20331 based on analyst consensus for Cobenfy sales projections2 ($ in millions) 2026 2027 2028 2029 2030 2031 2032 20331 $250- $359- $431- $474- $49
Slide 29: Near-term Priorities & Catalysts
Near-term Priorities & Catalysts Equity1 Priority & Catalyst Timing Secure external funding By early Q3 2026 Celea Therapeutics 35.4% Initiate Phase 3 SURPASS-IPF trial in IPF In early Q3 2026 Topline results from Phase 3 SURPASS-IPF trial in IPF H2 2029 Final results from Phase 1b tri
Slide 30: Analyst Coverage
LSE Main Market: PRTC Headquartered in Seaport, Boston 245,179,646 outstanding shares ~$220M PureTech Level Cash, Cash as of September 30, 2026 Equivalents as of June 30, 20261 ANALYST COVERAGE Peel Hunt LLP Shore Capital Investec Miles Dixon Sean Conroy Jens Lindqvist Singer Capital Markets Panmure
Slide 31: Appendix
PURETECH GIVING LIFE TO SCIENCE” 31
Slide 32: Our Innovative Approach to Development
Our Innovative Approach to Development Unlocking value from therapeutics with clinically-validated pharmacology CRITERIA APPROACH Development anchored to key validation/value inflection points Mechanism validated in prior human studies Capital deployed selectively as conviction increases Clear disea
Slide 33: Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF
Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF Adjusted Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicted Adjusted Mean (SE) Change
Slide 34: ELEVATE Achieved Primary and Key Secondary Endpoints
ELEVATE Achieved Primary and Key Secondary Endpoints Posterior Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Posterior Mean (SE) Change from Baseline in FVCpp over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicte
Slide 35: Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone
Versus Placebo, Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone in ELEVATE Trial Treatment Effect from Change in Forced Vital Capacity (FVC) and Percent Predicted Forced Vital Capacity (FVCpp) Across Arms 90% 87.5% 80.9% 80% 70% 57.4% 60% 54.1% 50% 47.2% 40% 28.3% 30% 20% 10%
Slide 36: PK Analysis Showed Deupirfenidone 825 mg TID Has ~50% Greater Exposure
PK Analysis From ELEVATE Showed That Deupirfenidone 825 mg TID Has ~50% Greater Exposure than Pirfenidone Analysis of Estimated AUC for Deupirfenidone ELEVATE PK Summary and Pirfenidone Deupirfenidone 550 mg Deupirfenidone 825 mg ▶ Deupirfenidone 825 mg TID had TID vs. Pirfenidone TID vs. Pirfenidon
Slide 37: Deupirfenidone Had Favorable Tolerability in ELEVATE Trial
Deupirfenidone Had Favorable Tolerability in ELEVATE Trial Summary of Most Common (≥10% in Any Treatment Group) TEAEs by SOC, PT, and Treatment Group (Safety Set) Placebo Pirfenidone Deupirfenidone Deupirfenidone TID 801 mg TID 550 mg TID 825 mg TID SOC/PT (N=65) (N=63) (N=65) (N=64) n (%) n (%) n (
Slide 38: Financial Highlights
Financial Highlights June 30, 2026 December 31, 2025 $ millions $ millions Cash Flow and Liquidity Cash and Cash Equivalents 121.3 252.5 Short-term investments 98.8 24.8 Consolidated Cash, cash equivalents and short-term investments 220.1 277.3 Less: Cash and Cash Equivalents held at non-wholly-owne
Slide 39: Non-IFRS Measures
Non-IFRS Measures Reported Performance Reported performance considers all factors that have affected the results of our business, as reflected in our condensed consolidated financial statements. Core Performance Core performance measures are alternative performance measures which are adjusted and no
PureTech Health — Investor Presentation (October 2026) on 6ix